咪喹莫特在皮肤肿瘤中的应用与机制

doi:10.3760/cma.j.issn.1673422X.2016.12.019

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (12): 953-955.doi: 10.3760/cma.j.issn.1673422X.2016.12.019

• 综述 • 上一篇

咪喹莫特在皮肤肿瘤中的应用与机制

张付贺, 石磊, 罗敏, 王秀丽

安徽医科大学上海皮肤病临床学院光医学治疗科上海市皮肤病医院同济大学医学院光医学研究所光医学治疗科

出版日期:2016-12-08 发布日期:2016-11-02
基金资助:
国家自然科学基金（81472796）；上海市青年科技英才扬帆计划(15YF1410700)

Application and mechanism of imiquimod in skin tumor

ZHANG Fu-He, SHI Lei, LUO Min, WANG Xiu-Li

Department of Photomedicine，Shanghai Skin Disease Clinical College of Anhui Medical University, Department of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine Institute of Photomedicine,Shanghai 200443, China

Online:2016-12-08 Published:2016-11-02
Supported by:
National Natural Science Foundation of China (81472796)； Shanghai Youth Scientific and Technological Excellence Sail Program (15YF1410700)

摘要/Abstract

摘要： 咪喹莫特是一种人工合成的Toll样受体7激动剂，在皮肤科主要用于治疗基底细胞癌、鳞状细胞癌、皮肤转移性黑色素瘤和外阴上皮内瘤变，具有激活天然免疫和特异性免疫、诱导肿瘤细胞自噬和凋亡、抑制肿瘤血管的形成等作用，有着极大的临床应用潜力。

关键词: 肿瘤, 免疫, 咪喹莫特

Abstract: Imiquimod is a synthetic Tolllike receptor7 agonist, mainly used for the treatment of basal cell carcinoma, squamous cell carcinoma and metastatic melanoma and vulvar intraepithelial neoplasia. Since imiquimod has activated innate immunity and specific immunity, inducing tumor cells autophagy and apoptosis, inhibit the formation of tumor blood vessels and other effects, it will has a great potential clinical application in the future.

Key words: Neoplasms, Immunity, Imiquimod

张付贺, 石磊, 罗敏, 王秀丽. 咪喹莫特在皮肤肿瘤中的应用与机制[J]. 国际肿瘤学杂志, 2016, 43(12): 953-955.

ZHANG Fu-He, SHI Lei, LUO Min, WANG Xiu-Li. Application and mechanism of imiquimod in skin tumor[J]. Journal of International Oncology, 2016, 43(12): 953-955.

参考文献

［1］ Lecluse LL, Spuls PI. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basalcell carcinoma: a single blind, noninferiority, randomised controlled trial: a critical appraisal［J］. Br J Dermatol, 2015, 172(1): 810. DOI: 10.1111/bjd.13460. ［2］ Papakostas D, Stockfleth E. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod［J］. Future Oncol, 2015, 11(22): 29852990. DOI: 10.2217/fon.15.192. ［3］ Kawasaki M, Kawakami N, Kawai K, et al. Cutaneous mucormycosis in bone marrow transplantation recipients［J］. Eur J Dermatol, 2012, 22（4）: 578579.DOI: 10.1684/ejd.2012.1770. ［4］ Aspord C, Tramcourt L, Leloup C, et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization［J］. J Invest Dermatol, 2014, 134（10）: 25512561. DOI: 10.1038/jid.2014.194. ［5］ Kim JM, Lee HJ, Kim SH, et al. Efficacy of 5% imiquimod cream on vulvar intraepithelial neoplasia in Korea: pilot study［J］. Ann Dermatol, 2015, 27（1）: 6670. DOI: 10.5021/ad.2015.27.1.66. ［6］ Samo M, Choudhary NR, Riebe KJ，et al. Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface［J］. Vaccine， 2016， 34(9): 11931200. DOI: 10.1016/j.vaccine.2016.01.024. ［7］ Bubna AK. Imiquimodits role in the treatment of cutaneous malignancies［J］. Indian J Pharmacol， 2015， 47(4): 354359. DOI: 10.4103/02537613.161249. ［8］ Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88dependent signaling pathway［J］. Nat Immunol, 2002, 3（2）: 196200. DOI: 10.1038/ni758. ［9］ Singh M, Khong H, Dai Z, et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation［J］. J Immunol, 2014, 193（9）: 47224731. DOI: 10.4049/jimmunol.1401160. ［10］ Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weaklyimmunogenic protein prototype vaccine［J］. Vaccine, 2006, 24（11）: 19581965. DOI: 10.1016/J.vaccine.2005.10.045. ［11］ RoldánMarín R, ToussaintCaire S. Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response［J］. Dermatol Ther (Heidelb), 2015, 5(4): 265272. ［12］ Huang SW, Chang SH, Mu SW， et al.Imiquimod activates p53dependent apoptosis in a human basal cell carcinoma cell line［J］. J Dermatol Sci, 2016, 81(3):182191. DOI: 10.1016/j.jdermsci.2015.12.011. ［13］ Huang SW, Kao JK, Wu CY, et al. Targeting aerobic glycolysis and HIF1alpha expression enhance imiquimodinduced apoptosis in cancer cells［J］. Oncotarget, 2014, 5（5）: 13631381. DOI: 10.18632/oncotarget.1734. ［14］ Sohn KC, Li ZJ, Choi DK, et al. Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20［J］. PLoS One, 2014, 9: e95337. DOI: 10.1371/journal.pone.0095337. e Collection 2014. ［15］ Huang SW, Chang CC, Lin CC, et al. Mcl1 determines the imiquimodinduced apoptosis but not imiquimodinduced autophagy in skin cancer cells［J］. J Dermatol Sci， 2012， 65(3): 170178. DOI: 10.1016/j.jdermsci.2011.11.001. ［16］ Wang ST, Huang SW, Kao JK, et al. Imiquimodinduced AMPK activation causes translation attenuation and apoptosis but not autophagy［J］. J Dermatol Sci, 2015, 78（2）: 108116. DOI: 10.1016/j.jdermsci.2015.02.008. ［17］ Ahn MY, Kwon SM, Cheong HH, et al. Tolllike receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis［J］. J Oral Pathol Med, 2012, 41（7）: 540546. DOI: 10.1111/j.16000714.2012.01158.x. ［18］ Aspord C, Tramcourt L, Leloup C, et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization［J］. J Invest Dermatol, 2014, 134（10）: 25512561. DOI: 10.1038/jid.2014.194. ［19］ Paul SP. Topical treatment of skin cancers and the risks of “fighting fire with fire”［C］. In: Clinical Cases in Skin Cancer Surgery and Treatment. Springer, 2016: 115125. DOI: 10.1007/9783319209371_11. ［20］ Yin T, He S, Wang Y. Toll like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model［J］. Mole Med Rep, 2015, 12(3): 35153520. DOI: 10.3892/mmr.2015.3885. ［21］ Savarese I, Papi F, D′Errico A, et al. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells［J］. Clin Exp Dermatol, 2015, 40(1): 2730. DOI: 10.1111/ced.12469.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.

咪喹莫特在皮肤肿瘤中的应用与机制

Application and mechanism of imiquimod in skin tumor

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价